AI-Driven Polypharmacology in Small-Molecule Drug Discovery

Area of Science:

• Drug discovery and development
• Computational chemistry
• Pharmacology

Background:

• Polypharmacology, the design of molecules targeting multiple therapeutic targets, addresses challenges like biological redundancy and drug resistance.
• It offers advantages over combination therapies by potentially synergizing effects, reducing adverse events, and improving patient compliance.

Purpose of the Study:

• To review the scientific rationale and applications of polypharmacology across various diseases.
• To explore the role of computational methods and artificial intelligence (AI) in accelerating polypharmacology drug discovery.
• To discuss the integration of omics data and pathway simulations in guiding multi-target drug design.

Main Methods:

• Review of scientific literature on polypharmacology.
• Exploration of computational approaches including ligand-based modeling, structure-based docking, network pharmacology, and systems biology.
• Analysis of recent advances in AI, such as deep learning, reinforcement learning, and generative models for multi-target agent discovery.

Main Results:

• Polypharmacology has shown success in oncology, neurodegeneration, metabolic disorders, and infectious diseases.
• AI-driven platforms are enabling de novo design of dual and multi-target compounds with demonstrated in vitro efficacy.
• Integration of omics data and pathway simulations aids in guiding multi-target design.

Conclusions:

• AI-enabled polypharmacology represents a significant advancement in drug discovery for complex diseases.
• It holds the potential to deliver more effective, personalized therapies by addressing biological complexity.
• Further research is needed to address the challenges and limitations of current AI approaches in polypharmacology.